Eliem Therapeutics is a clinical-stage biotechnology company.

Our focus is to advance the clinical development of assets for the treatment of hyperexcitability disorders, such as chronic pain. Patients desperately need access to safe, efficacious, and well-tolerated non-opioid therapies to remedy chronic pain. Drugs currently prescribed for pain relief have limited efficacy in addition to tolerability and safety issues, which severely limit their therapeutic benefit.


Eliem Therapeutics will leverage our world-class expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline. We are pioneering a new generation of analgesics to facilitate a better quality of life for patients.

Leadership Team

Andrew Levin
Bio +
Andrew Levin

Co-Founder and Interim Chief Executive Officer

Andrew Levin, MD, PhD is Co-Founder and Interim Chief Executive Officer of Eliem Therapeutics. In addition to co-founding Eliem, Andrew spearheads drug discovery efforts at RA Capital Management, LLC that have led to the formation of several companies and serves as a Managing Director on the Investment Team. Previously, Andrew was a Vice President at H.I.G. BioVentures, and prior to that served as the Director of Pharmaceutical Sciences for the Clinton Health Access Initiative. He holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School.

X
Valerie Morisset
Bio +
Valerie Morisset

Co-Founder and Chief Scientific Officer

Valerie Morisset, PhD is Co-Founder and Chief Scientific Officer of Eliem Therapeutics. Valerie has more than 20 years’ experience in the pharmaceutical industry, with positions of increasing responsibility at Novartis, GSK, Convergence, and Biogen. Prior to joining Eliem, Valerie was a founding venture partner at Bridge Valley Ventures. She co-founded Convergence Pharmaceuticals, where she established and led the Biology and Translational Medicine team, and was instrumental in the sale of Convergence to Biogen for $675M in 2015. Valerie subsequently joined Biogen in a senior leadership role. She has worked extensively in the field of drug development for Pain and across a number of other therapeutic areas including Neurology, Psychiatry, Gastrointestinal Disorders and Sensory Biology. Valerie trained as an electrophysiologist and completed her PhD at the University of Bordeaux.

X
Simon Tate
Bio +
Simon Tate

Partner at Bridge Valley Ventures

Simon Tate, PhD is a partner at Bridge Valley Ventures and has 30 years of experience in R&D. Simon has spent most of his career working in the fields of Pain and Neuroscience. He was one of the founders of Convergence Pharmaceuticals, and as Chief Scientific Officer and head of R&D, led Convergence to its successful acquisition by Biogen for $675M in 2015. Following this acquisition, Simon joined Biogen where he assumed the role of Vice President and Head of the Pain Therapeutic Area. Prior to Convergence, Simon was Vice President and Head of Pain, Epilepsy, and Migraine drug discovery and early development in GSK, where he held senior roles in Neurology, Psychiatry, and Discovery Sciences during his 20-year career. Originally trained as a Biochemist, Simon graduated from the University of Dundee, where he had the privilege to work with Sir Philip Cohen, who was, at the time, the world’s third most cited professor.

X
David-Alexandre C. Gros
Bio +
David-Alexandre C. Gros

Co-Founder and Chief Executive Officer of Imbria Pharmaceuticals

D.A. Gros, MD, MBA is Co-Founder and Chief Executive Officer of Imbria Pharmaceuticals. D.A. has extensive experience in building and financing bio-pharmaceutical companies as well as developing and executing growth strategies. He joined Eliem from Neurocrine Biosciences where he was President, Chief Operating Officer, and acting Chief Financial Officer. Prior to Neurocrine, he served as Chief Business Officer and Principal Financial Officer of Alnylam Pharmaceuticals, and as Chief Strategy Officer of Sanofi. Before joining Sanofi, D.A. held positions of increasing responsibility with a focus on biotechnology and pharmaceuticals in investment banking at Centerview Partners and Merrill Lynch, and in consulting at McKinsey & Company. He holds an MD from Johns Hopkins University School of Medicine, an MBA from Harvard Business School, and an AB from Dartmouth College.

X

Contact

Contact us for more information:

investorrelations@eliemtx.com